ARA-290 vs PDA
Both ARA-290 and PDA are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Side-by-Side
| Attribute | ARA-290 | PDA |
|---|---|---|
| Evidence Grade | B | C+ |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved — newer compounded analog of BPC-157 |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | 200–500 mcg daily (subcutaneous) |
| Clinics Indexed | 9 | 41 |
| Categories | anti-inflammatory, neuroprotection | recovery, anti-inflammatory |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.